| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/29/2023 | 31.58% | Wedbush | → $12 | Reiterates | Outperform → Outperform |
| 09/22/2023 | 31.58% | Barclays | $31 → $12 | Maintains | Overweight |
| 09/22/2023 | 196.05% | B of A Securities | $41 → $27 | Maintains | Buy |
| 09/22/2023 | 97.37% | Guggenheim | $25 → $18 | Maintains | Buy |
| 09/22/2023 | 53.51% | Evercore ISI Group | $30 → $14 | Maintains | Outperform |
| 09/22/2023 | 97.37% | HC Wainwright & Co. | $32 → $18 | Maintains | Buy |
| 09/22/2023 | -12.28% | Wells Fargo | $24 → $8 | Downgrades | Overweight → Equal-Weight |
| 09/21/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 09/19/2023 | 228.95% | Evercore ISI Group | $30 → $30 | Maintains | Outperform |
| 09/06/2023 | 228.95% | Evercore ISI Group | → $30 | Reinstates | Outperform → Outperform |
| 08/18/2023 | 108.33% | Piper Sandler | $22 → $19 | Maintains | Neutral |
| 08/07/2023 | 250.88% | HC Wainwright & Co. | $35 → $32 | Reiterates | Buy → Buy |
| 07/21/2023 | 185.09% | JP Morgan | → $26 | Initiates Coverage On | → Overweight |
| 07/18/2023 | 283.77% | Canaccord Genuity | $37 → $35 | Maintains | Buy |
| 06/21/2023 | 152.19% | Wedbush | → $23 | Reiterates | Outperform → Outperform |
| 06/07/2023 | 141.23% | Piper Sandler | → $22 | Assumes | → Neutral |
| 06/01/2023 | 283.77% | HC Wainwright & Co. | $22 → $35 | Reiterates | → Buy |
| 05/22/2023 | 228.95% | TD Cowen | → $30 | Initiates Coverage On | → Outperform |
| 05/02/2023 | 141.23% | HC Wainwright & Co. | $40 → $22 | Maintains | Buy |
| 05/02/2023 | 327.63% | B of A Securities | $52 → $39 | Maintains | Buy |
| 05/02/2023 | 185.09% | Evercore ISI Group | $36 → $26 | Maintains | Outperform |
| 05/02/2023 | 163.16% | Wells Fargo | $28 → $24 | Maintains | Overweight |
| 05/02/2023 | 152.19% | Guggenheim | $40 → $23 | Maintains | Buy |
| 04/17/2023 | 217.98% | Wedbush | $30 → $29 | Maintains | Outperform |
| 03/01/2023 | 305.7% | Guggenheim | → $37 | Initiates Coverage On | → Buy |
| 02/28/2023 | 360.53% | Canaccord Genuity | $44 → $42 | Maintains | Buy |
| 02/24/2023 | 338.6% | HC Wainwright & Co. | → $40 | Reiterates | → Buy |
| 02/22/2023 | 382.46% | Canaccord Genuity | $40 → $44 | Maintains | Buy |
| 02/21/2023 | 404.39% | Piper Sandler | $42 → $46 | Maintains | Overweight |
| 02/21/2023 | 228.95% | Wedbush | → $30 | Upgrades | Neutral → Outperform |
| 02/21/2023 | 239.91% | Barclays | $37 → $31 | Maintains | Overweight |
| 02/21/2023 | 338.6% | HC Wainwright & Co. | $36 → $40 | Reiterates | → Buy |
| 02/17/2023 | 294.74% | HC Wainwright & Co. | → $36 | Reiterates | → Buy |
| 01/30/2023 | 338.6% | Canaccord Genuity | $33 → $40 | Maintains | Buy |
| 01/11/2023 | 360.53% | Piper Sandler | $38 → $42 | Maintains | Overweight |
| 12/14/2022 | 141.23% | Stifel | → $22 | Initiates Coverage On | → Hold |
| 12/05/2022 | 207.02% | Wells Fargo | → $28 | Initiates Coverage On | → Overweight |
| 10/20/2022 | 316.67% | SVB Leerink | $45 → $38 | Maintains | Outperform |
| 10/17/2022 | 294.74% | HC Wainwright & Co. | $42 → $36 | Maintains | Buy |
| 10/14/2022 | 316.67% | Piper Sandler | $39 → $38 | Maintains | Overweight |
| 08/08/2022 | 360.53% | HC Wainwright & Co. | $46 → $42 | Maintains | Buy |
| 08/05/2022 | 393.42% | SVB Leerink | $42 → $45 | Maintains | Outperform |
| 07/26/2022 | 349.56% | Piper Sandler | $40 → $41 | Maintains | Overweight |
| 07/14/2022 | 360.53% | Canaccord Genuity | → $42 | Assumes | → Buy |
| 05/17/2022 | 404.39% | HC Wainwright & Co. | $45 → $46 | Maintains | Buy |
| 05/06/2022 | 338.6% | Piper Sandler | $42 → $40 | Maintains | Overweight |
| 03/31/2022 | 360.53% | Piper Sandler | → $42 | Initiates Coverage On | → Overweight |
| 02/28/2022 | 393.42% | HC Wainwright & Co. | → $45 | Initiates Coverage On | → Buy |
| 12/16/2021 | 338.6% | Barclays | $36 → $40 | Maintains | Overweight |
| 12/16/2021 | 360.53% | SVB Leerink | $37 → $42 | Maintains | Outperform |
| 08/17/2021 | 305.7% | SVB Leerink | $27 → $37 | Maintains | Outperform |
| 05/27/2021 | 393.42% | Canaccord Genuity | $48 → $45 | Maintains | Buy |
| 05/26/2021 | 108.33% | Wedbush | → $19 | Downgrades | Outperform → Neutral |
| 05/17/2021 | 426.32% | Canaccord Genuity | $51 → $48 | Maintains | Buy |
| 02/03/2021 | 459.21% | Canaccord Genuity | $28 → $51 | Maintains | Buy |
What is the target price for Travere Therapeutics (TVTX)?
The latest price target for Travere Therapeutics (NASDAQ: TVTX) was reported by Wedbush on September 29, 2023. The analyst firm set a price target for $12.00 expecting TVTX to rise to within 12 months (a possible 31.58% upside). 40 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Travere Therapeutics (TVTX)?
The latest analyst rating for Travere Therapeutics (NASDAQ: TVTX) was provided by Wedbush, and Travere Therapeutics reiterated their outperform rating.
When is the next analyst rating going to be posted or updated for Travere Therapeutics (TVTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Travere Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Travere Therapeutics was filed on September 29, 2023 so you should expect the next rating to be made available sometime around September 29, 2024.
Is the Analyst Rating Travere Therapeutics (TVTX) correct?
While ratings are subjective and will change, the latest Travere Therapeutics (TVTX) rating was a reiterated with a price target of $0.00 to $12.00. The current price Travere Therapeutics (TVTX) is trading at is $9.12, which is within the analyst's predicted range.